ESTRO 2024 - Abstract Book

S2379

Clinical - Urology

ESTRO 2024

Conclusion:

Treatment with empty bladder protocol and SBRT is feasible with acute bladder toxicity similar to full bladder (PRIME trial Grade 2 toxicity 31.8% vs 27.5% with empty bladder) [2]. The empty bladder is not often completely empty (median volume 81.4cc). The empty bladder volume does not significantly vary between simulation and treatment.

Keywords: prostate cancer, SBRT, empty bladder

References:

1. Vedang Murthy et al., “Study Protocol of a Randomised Controlled Trial of Prostate Radiotherapy in High -Risk and Node- Positive Disease Comparing Moderate and Extreme Hypofractionation (PRIME TRIAL).” DOI: 10.1016/S0167 8140(23)08750-9

2. Murthy et al., “OC -0924 Prostate RT In High Risk or N+ Moderate vs Extreme Hypofractionation (PRIME): An Interim Analysis.” DOI: 10.1136/bmjopen -2019-034623

1025

Poster Discussion

Ga68PSMAPET & MR based prostate Boost for dose Escalation(PROBE):Initial results of a phase II trial

Maneesh Singh 1 , Aparna Katdare 2 , Archi Agrawal 3 , Suchismita Ghosh 3 , Reena Phurailatpam 4 , Divya Patil 4 , Mahima Tiwari 4 , Sayak Choudhury 3 , Nazneen Husain Chougle 1 , Muhammad Anaz RC 1 , Akash Pawar 5 , Priyamvada Maitre 1 , Vedang Murthy 1 1 Tata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India. 2 Tata Memorial Centre, Homi Bhabha National Institute, Department of Radiodiagnosis, Mumbai, India. 3 Tata Memorial Centre, Homi Bhabha National Institute, Department of Nuclear Medicine, Mumbai, India. 4 Tata Memorial Centre, Homi Bhabha National Institute, Department of Medical Physics, Mumbai, India. 5 Tata Memorial Centre, Homi Bhabha National Institute, Department of Biostatistics, Clinical Research Secretariat, Mumbai, India

Purpose/Objective:

To investigate the feasibility and safety of combined prostate-specific-membrane antigen targeting positron emission tomography targeting (Ga68 PSMA-PET) and multiparametric magnetic resonance imaging (mpMRI) based planning for focal dose escalation to the dominant intra-prostatic lesion (DIL) during definitive prostate stereotactic ablative radiotherapy (SBRT).